COVID-19 vaccine prioritisation for type 1 and type 2 diabetes

Simple item page
dc.contributor.authorPowers, Alvin C.
dc.contributor.authorAronoff, David M.
dc.contributor.authorEckel, Robert H.
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2025-04-10T14:01:25Z
dc.date.available2025-04-10T14:01:25Z
dc.date.issued2021
dc.eprint.versionFinal published version
dc.identifier.citationPowers AC, Aronoff DM, Eckel RH. COVID-19 vaccine prioritisation for type 1 and type 2 diabetes. Lancet Diabetes Endocrinol. 2021;9(3):140-141. doi:10.1016/S2213-8587(21)00017-6
dc.identifier.urihttps://hdl.handle.net/1805/46965
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/S2213-8587(21)00017-6
dc.relation.journalThe Lancet Diabetes & Endocrinology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectCOVID-19
dc.subjectType 1 diabetes mellitus
dc.subjectHealth priorities
dc.titleCOVID-19 vaccine prioritisation for type 1 and type 2 diabetes
dc.typeArticle
ul.alternative.fulltexthttps://pmc.ncbi.nlm.nih.gov/articles/PMC7831734/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Powers2021Covid-PP.pdf
Size:
49.25 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works